Clinuvel PharmaceuticalsvsIntel

CUVL and INTC stock compared: price, dividend, valuation and results, from SEC filings.

CUVL

Clinuvel Pharmaceuticals Limited

$4.66

Value $235M

-1.06%
CUVL's page

INTC

Intel Corporation

$51.96

Value $276B

-7.02%
INTC's page

Clinuvel Pharmaceuticals (CUVL) has a market value of $235M and Intel (INTC) $276B. Over the last year, with dividends, CUVL moved -32.5% and INTC +49.5%. Dividend yield: CUVL 0.71%, INTC none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    CUVL$235M

    INTC$276B

    INTC is 1,175 times CUVL

  • Revenue, 12 months

    CUVL$64M

    INTC$59.9B

    INTC is 931 times CUVL

  • Net income, 12 months

    CUVL$23M

    INTC-$12.0B

  • Operating margin

    CUVL43.4%

    INTC2.9%

    40.5 points apart

  • ROIC

    CUVL11.7%

    INTC0.9%

    10.8 points apart

  • P/E

    CUVL10.1

    INTC–

  • Dividend yield

    CUVL0.7%

    INTC0.0%

    0.7 points apart

  • 5-year return

    CUVL-79.3%

    INTC+14.3%

    93.6 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

CUVL-79.3%

INTC+14.3%

10020030020222023202420252026
Returns by period
PeriodCUVLWith dividendsINTCWith dividends
1 year since November 19, 2025-32.5%Price -32.9%+49.5%Price +49.5%
3 years since November 20, 2023-54.9%-23.3% a yearPrice -55.3%+18.9%+5.9% a yearPrice +17.3%
5 years since November 19, 2021-79.3%-27.0% a yearPrice -79.6%+14.3%+2.7% a yearPrice +6.0%
10 years since November 21, 2016-20.9%-2.3% a yearPrice -22.3%+83.7%+6.3% a yearPrice +50.0%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

CUVLClinuvel PharmaceuticalsINTCIntel

Valuation

CUVLINTC
Valuation
Price$4.66$51.96
Market value$235M$276B
Enterprise value (EV)$61M$272B
P/E10.1–
P/E, 5-year median15.9–
P/B1.32.4
EV/EBIT2.2154.5
Free cash flow yield5.0%1.4%

Results and growth

CUVLINTC
Results and growth
Revenue, 12 months$64M$59.9B
Net income, 12 months$23M-$12.0B
Free cash flow, 12 months$12M$3.8B
Earnings per share, 12 months$0.46-$2.42
Revenue growth, year on year5.2%-0.5%
Revenue growth a year, past+5.4%over 2 years-7.5%over 5 years
EPS growth a year, past+0.0%over 2 years–

Margins and returns on capital

CUVLINTC
Margins and returns on capital
Gross margin82.9%39.9%
Operating margin43.4%2.9%
Net margin36.0%-20.1%
ROIC11.7%0.9%
ROE12.3%-11.3%

Balance sheet

CUVLINTC
Balance sheet
Cash$174M$54.0B
Total debt$1.3M$50.1B
Net debt / EBITDA-6.2-0.3
Interest cover–1.5×

Dividends and buybacks

CUVLINTC
Dividends and buybacks
Dividend yield0.7%–
Dividend per share, 12 months$0.03–
Dividend growth a year, past––
Buyback yield––
Shareholder yield0.7%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: CUVL or INTC

Didn't find what you were looking for?

Ask us
Which is bigger, Clinuvel Pharmaceuticals or Intel?

By market value, Intel ($276B) is about 1,175.2 times Clinuvel Pharmaceuticals ($235M), at today's prices.

How did CUVL and INTC stock do over the last 10 years?

Since November 21, 2016, CUVL's price moved -22.3% and INTC's +50.0%. With dividends: CUVL -20.9% (-2.3% a year), INTC +83.7% (+6.3% a year). Past returns do not predict future ones.

Which pays the higher dividend, CUVL or INTC?

The dividend yield at today's price is 0.71% for Clinuvel Pharmaceuticals and none for Intel. Over the last twelve months they paid $0.03 and – per share.

Which has the higher profit margins, Clinuvel Pharmaceuticals or Intel?

Over the last twelve months, the net margin was 36.0% for Clinuvel Pharmaceuticals and -20.1% for Intel, and the operating margin 43.4% and 2.9%. Revenue was $64M and $59.9B.

Which is the better investment, Clinuvel Pharmaceuticals or Intel?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.